Nano-X Imaging Ltd. (NASDAQ: NNOX), a company focused on transforming preventive healthcare through an integrated medical imaging and services platform, has announced a securities purchase agreement with a single long-term institutional investor for a registered direct offering. The offering is expected to generate gross proceeds of approximately $8 million before fees and expenses, providing the company with additional capital to advance its strategic initiatives.
Under the terms of the agreement, Nano-X will sell 8 million ordinary shares, or prefunded warrants in lieu thereof, together with warrants to purchase up to an additional 8 million ordinary shares. The combined purchase price is set at $1.00 per share and accompanying warrant. The warrants will have an exercise price of $1.15 per share, become exercisable six months after issuance, and will expire five years following the closing. The offering is anticipated to close on or about Aug. 7, 2026, subject to customary closing conditions.
The company stated that it intends to use the net proceeds for working capital and general corporate purposes. This financing comes at a critical time as Nano-X continues to develop and commercialize its innovative imaging technologies, including the Nanox.ARC, a cost-effective 3D multi-source digital tomosynthesis system, and its suite of AI-driven solutions designed to augment radiology workflows and support early disease detection.
A.G.P./Alliance Global Partners is serving as the sole placement agent for the transaction. The full press release can be viewed at https://ibn.fm/5fNi8.
The significance of this offering extends beyond the immediate capital infusion. Nano-X is positioned at the intersection of medical imaging, artificial intelligence, and cloud-based healthcare services, aiming to lower barriers to adoption and expand access to preventive care. By securing additional funding, the company can continue to invest in its integrated platform, which includes Nanox.AI algorithms, Nanox.CLOUD for secure data management, and Nanox.MARKETPLACE, along with USARAD Holdings for teleradiology services.
Moreover, this direct offering reflects investor confidence in Nano-X's long-term vision, despite the dilutive effect of issuing new shares and warrants. The company's focus on early detection and preventive health aligns with broader industry trends toward value-based care and the increasing utilization of imaging in non-traditional settings. As Nano-X progresses toward closing this offering, it will be better equipped to execute its growth strategy, potentially enhancing its competitive position in the medical imaging market.
For more information about Nano-X Imaging, visit https://www.nanox.vision/.
